MA46712A - Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire - Google Patents

Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Info

Publication number
MA46712A
MA46712A MA046712A MA46712A MA46712A MA 46712 A MA46712 A MA 46712A MA 046712 A MA046712 A MA 046712A MA 46712 A MA46712 A MA 46712A MA 46712 A MA46712 A MA 46712A
Authority
MA
Morocco
Prior art keywords
combinations
acid chelators
fgfr4 inhibitors
biliary acid
biliary
Prior art date
Application number
MA046712A
Other languages
English (en)
Inventor
Robin Alec Fairhurst
Porta Diana Graus
Jacqueline Kinyamu-Akunda
Andreas Joerg Mahl
Luigi Manenti
Andreas Weiss
Armin Wolf
Kuno Wuersch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA46712A publication Critical patent/MA46712A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046712A 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire MA46712A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662416222P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
MA46712A true MA46712A (fr) 2019-09-11

Family

ID=60661908

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046712A MA46712A (fr) 2016-11-02 2017-11-01 Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire

Country Status (17)

Country Link
US (1) US11229643B2 (fr)
EP (1) EP3534902B1 (fr)
JP (2) JP7394623B2 (fr)
KR (1) KR102362648B1 (fr)
CN (2) CN109922804B (fr)
AU (1) AU2017354082B2 (fr)
CA (1) CA3042475C (fr)
ES (1) ES2934341T3 (fr)
IL (1) IL266293B (fr)
MA (1) MA46712A (fr)
MX (1) MX387222B (fr)
PL (1) PL3534902T3 (fr)
PT (1) PT3534902T (fr)
RU (1) RU2742033C2 (fr)
SG (1) SG11201903911UA (fr)
WO (1) WO2018083603A1 (fr)
ZA (1) ZA201902744B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
CN112759593A (zh) * 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582652T3 (es) 2006-02-10 2016-09-14 Genentech, Inc. Anticuerpos anti-FGF19 y métodos de uso de los mismos
EP1918376A1 (fr) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques
EP2124884B1 (fr) * 2006-12-22 2019-07-10 Ironwood Pharmaceuticals, Inc. Compositions contenant des chelateurs d'acide biliaire pour le traitement des troubles oesphagiens
CL2008000947A1 (es) 2007-04-02 2008-10-10 Genentech Inc Uso de un antagonista de la proteina beta-klotho (klb) para tratar trastornos asociados a la expresion o actividad de klb.
US8524212B2 (en) * 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010026291A1 (fr) 2008-09-03 2010-03-11 Licentia Ltd. Matières et procédés pour bloquer l'invasion par les cellules cancéreuses sur fgfr4
US20100330175A1 (en) * 2009-06-24 2010-12-30 Jobdevairakkam Christopher N Cross-linked polyallylamine tablet core
CA2828890A1 (fr) 2011-04-07 2012-10-11 Genentech, Inc. Anticorps anti-fgfr4 et procedes d'utilisation
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
ES2915851T3 (es) * 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
WO2014105849A1 (fr) 2012-12-28 2014-07-03 Xoma (Us) Llc Anticorps spécifiques contre le fgfr4 et méthodes d'utilisation
WO2014165287A1 (fr) 2013-03-12 2014-10-09 The Translational Genomics Research Institute Clones d'hybridome et anticorps monoclonaux dirigés contre le facteur de croissance 4 des fibroblastes
WO2014145909A2 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Composés pyrimido-diazépinone et procédés de traitement de troubles
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
PH12016500676B1 (en) 2013-10-18 2022-07-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
TN2016000115A1 (en) 2013-10-25 2017-07-05 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
WO2015107171A1 (fr) 2014-01-17 2015-07-23 Sanofi Méthodes d'identification de patients souffrant d'un cancer du foie pour lesquels un traitement avec un anticorps anti-fgfr4 antagoniste est plus à même d'être bénéfique
AU2015277438B2 (en) * 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016023894A1 (fr) 2014-08-11 2016-02-18 U3 Pharma Gmbh Anticorps anti-fgfr4 humain
JP6585167B2 (ja) * 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016151501A1 (fr) * 2015-03-25 2016-09-29 Novartis Ag Combinaisons pharmaceutiques
EP3095465A1 (fr) * 2015-05-19 2016-11-23 U3 Pharma GmbH Combinaison d'un inhibiteur de fgfr4 et d'un chélateur d'acides biliaires

Also Published As

Publication number Publication date
JP7394623B2 (ja) 2023-12-08
US20200261444A1 (en) 2020-08-20
CN117257800A (zh) 2023-12-22
BR112019008787A2 (pt) 2019-07-16
CN109922804B (zh) 2023-11-17
SG11201903911UA (en) 2019-05-30
CN109922804A (zh) 2019-06-21
KR102362648B1 (ko) 2022-02-11
MX2019005194A (es) 2019-08-05
EP3534902A1 (fr) 2019-09-11
ZA201902744B (en) 2021-08-25
WO2018083603A1 (fr) 2018-05-11
AU2017354082A1 (en) 2019-05-23
RU2742033C2 (ru) 2021-02-01
IL266293A (en) 2019-06-30
IL266293B (en) 2022-07-01
RU2019116061A3 (fr) 2020-12-04
CA3042475A1 (fr) 2018-05-11
PT3534902T (pt) 2022-12-07
PL3534902T3 (pl) 2023-03-27
MX387222B (es) 2025-03-18
JP2022033766A (ja) 2022-03-02
RU2019116061A (ru) 2020-12-04
AU2017354082B2 (en) 2023-07-27
ES2934341T3 (es) 2023-02-21
EP3534902B1 (fr) 2022-11-23
KR20190082256A (ko) 2019-07-09
JP2019533701A (ja) 2019-11-21
CA3042475C (fr) 2024-01-16
US11229643B2 (en) 2022-01-25

Similar Documents

Publication Publication Date Title
EP3454844A4 (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
PL3761980T3 (pl) Związki aminokwasowe i sposoby zastosowania
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
EP3630748A4 (fr) Petites molécules inhibitrices d'ire1
EP3373981A4 (fr) Identification et caractérisation de nouvelles molécules d'inhibiteur de corrosion
EP3317273A4 (fr) Inhibiteurs d'egfr et méthodes d'utilisation de ceux-ci
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
MA47179A (fr) Composition d'acide dicarboxylique mannuronique
PL3262183T3 (pl) Test na obecność i wrażliwość bakterii na środki przeciwdrobnoustrojowe
EP3691992A4 (fr) Compositions et procédés d'élimination de métaux lourds de soutions d'acide phosphorique
DK3510049T5 (da) Varianter af sur alfa-glucosidase og anvendelser deraf
HRP20211272T8 (hr) 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
EP3390457A4 (fr) Fabrication de nanocellulose et d'intermédiaires de celle-ci en utilisant de d'acide oxalique dihydraté
DK3710036T3 (da) Stable ascorbic acid compositions and methods of using the same
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3402572A4 (fr) Compositions et méthodes de traitement d'états inflammatoires allergiques
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
EP3113613A4 (fr) Compositions d'ester de choline de l'acide lipoïque et procédés d'utilisation correspondants
EP3415524A4 (fr) INHIBITEUR D'EXPRESSION DE L'a-SYNUCLÉINE